stockrowDrug Manufacturers General industry stocks
The Drug Manufacturers General industry has 21 US-listed companies on stockrow and is part of the Healthcare sector, with a combined market value of $4.54T. Eli Lilly and Company (LLY) is the largest at $1.28T, followed by Johnson & Johnson and AbbVie Inc.. The median Drug Manufacturers General stock trades at 26.5× trailing earnings, above the market median of 17.8×, with a median net margin of 7.31% (market: 1.14%). Median revenue growth over the last twelve months is 6.72%. 15 of the 21 pay a dividend; the median yield among payers is 2.32%.
Drug Manufacturers General medians
| Metric | Industry | Market |
|---|---|---|
| P/E | 26.5× | 17.8× |
| P/S | 3.5× | 1.9× |
| P/B | 5.3× | 1.7× |
| Price to free cash flow | 21.7× | 14.0× |
| EV/EBITDA | 14.7× | 10.9× |
| EV/Sales | 4.1× | 2.1× |
| Earnings yield | 2.41% | 1.54% |
| Free cash flow yield | 4.07% | 0.92% |
| Gross margin | 73.0% | 46.0% |
| Operating margin | 18.3% | 0.00% |
| Net margin | 7.31% | 1.14% |
| Free cash flow margin | 18.6% | 0.00% |
| Return on equity | 5.80% | 1.01% |
| Return on assets | 2.28% | 0.00% |
| Return on invested capital | 6.26% | 0.00% |
| Revenue growth (TTM) | 6.72% | 7.71% |
| EPS growth (last fiscal year) | 21.8% | 14.0% |
| Revenue growth, 5-year CAGR | 4.75% | 8.99% |
| Net income growth, 5-year CAGR | 0.00% | 0.00% |
| Debt to equity | 0.6× | 0.1× |
| Current ratio | 1.4× | 1.6× |
| Net debt to EBITDA | 1.2× | 0.6× |
| Dividend yield | 2.32% | 2.22% |
| Payout ratio | 0.6× | 0.3× |
| Market cap | $129.0B | $649.5M |
Today’s biggest moves
All 21 companies
Open in screener| LLY | Eli Lilly and Company | 1.28t | 1,366.60 | 0.14% | 44.34 | 31.90% | 45.51% | 0.49% |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 655.56b | 275.25 | 1.08% | 41.70 | 16.20% | 7.80% | 1.92% |
| ABBV | AbbVie Inc. | 509.50b | 290.81 | 0.89% | 50.05 | 15.61% | 10.68% | 2.38% |
| MRK | Merck & Co., Inc. | 362.53b | 146.65 | (0.20%) | 151.19 | 3.64% | 4.89% | 2.32% |
| NVS | Novartis AG | 296.42b | 162.31 | 0.23% | 30.91 | 17.49% | 1.76% | 2.92% |
| AZN | AstraZeneca PLC | 289.79b | 186.17 | (0.36%) | 26.18 | 17.68% | 7.32% | 1.72% |
| AMGN | Amgen Inc. | 248.84b | 460.73 | 0.10% | 26.51 | 24.14% | 8.15% | 2.16% |
| GILD | Gilead Sciences, Inc. | 207.84b | 166.96 | (0.36%) | — | (12.47%) | 6.54% | 1.95% |
| PFE | Pfizer Inc. | 170.31b | 29.32 | (1.87%) | 41.27 | 6.34% | 1.34% | 5.87% |
| NVO | Novo Nordisk A/S | 134.84b | 40.23 | (0.17%) | 10.12 | 34.09% | 11.14% | 4.46% |
| BMY | Bristol Myers Squibb Company | 129.04b | 62.12 | (1.60%) | 13.75 | 18.47% | 4.16% | 4.06% |
| SNY | Sanofi | 111.81b | 47.06 | 0.32% | 23.30 | 8.27% | 26.32% | 5.15% |
| GSK | GSK PLC Sponsored ADR | 101.04b | 50.31 | (0.20%) | 16.70 | 13.02% | 6.90% | 3.61% |
| BIIB | Biogen Inc. | 36.06b | 248.43 | 1.84% | 105.24 | 3.37% | 2.30% | — |
| OGN | Organon & Co. | 3.62b | 13.83 | 0.29% | 17.29 | 3.49% | (3.21%) | 0.58% |
| GRFS | Grifols, S.A. | 2.18b | 8.43 | (0.35%) | 18.23 | 6.02% | 10.87% | 1.12% |
| AMRN | Amarin Corporation PLC | 244.00m | 11.58 | 0.00% | — | (10.87%) | (22.33%) | — |
| NSRX | Nasus Pharma Ltd. | 34.08m | 2.83 | (2.75%) | — | — | — | — |
| MIRA | MIRA Pharmaceuticals, Inc. | 22.70m | 0.56 | 3.70% | — | 0.00% | — | — |
| SCLX | Scilex Holding Company | 11.96m | 1.69 | (0.59%) | — | (1,418.45%) | (28.55%) | — |
| MDCX | Medicus Pharma Ltd | 3.47m | 1.90 | 3.83% | — | 0.00% | — | — |